Skip to main content
Erschienen in: Osteoporosis International 6/2011

01.06.2011 | Original Article

Alteration of vitamin D metabolic enzyme expression and calcium transporter abundance in kidney involved in type 1 diabetes-induced bone loss

verfasst von: Y. Zhang, C. J. Papasian, H.-W. Deng

Erschienen in: Osteoporosis International | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study aimed to delineate the mechanism involved in type 1 diabetes-induced bone loss. The results revealed the alteration of vitamin D metabolic enzyme expression and the downregulation of renal calcium transporter abundance in type 1 diabetic mice.

Introduction

The purpose of this study was to investigate the changes of the expression of vitamin D metabolic enzymes and transcellular calcium-transporting proteins in kidneys from mice with experimentally induced diabetes.

Methods

Male DBA/2J mice were injected with either vehicle (control) or streptozotocin (STZ) daily for five consecutive days. Bone mineral density was measured by peripheral quantitative computerized tomography, and bone histomorphology was analyzed by Safranin O staining. Real-time PCR and Western blotting were applied to determine the expression of target genes and proteins.

Results

Type 1 diabetes produced high urinary calcium excretion and loss of trabecular bone measured at the proximal metaphysis of the tibia and the distal femur. Bone loss was associated with deterioration of trabecular bone microstructure. Quantified PCR results showed that mRNA expression level in the kidney of diabetic mice for 25-hydroxyvitamin D-24-hydroxylase was downregulated at week 10, while those for 25-hydroxyvitamin D-1α-hydroxylase were upregulated at week 20. In addition, mRNA expression levels for renal transient receptor potential V6, plasma membrane Ca-ATPase (PMCA)1b, and vitamin D receptor (VDR) genes were decreased in STZ-treated mice. Western blot analysis showed that protein expression of PMCA1b and VDR was significantly decreased in kidneys from STZ-treated mice compared to that of controls.

Conclusions

The limitation in this study is the lack of vitamin D, parathyroid hormone, and phosphorus levels in serum. However, the present study supports the conclusion that the underlying mechanism contributing to type 1 diabetes-associated bone loss may be alterations of vitamin D metabolic enzyme expression and associated decreases in expression of renal calcium transporters.
Literatur
1.
Zurück zum Zitat Tao B, Liu JM, Zhao HY, Sun LH, Wang WQ, Li XY, Ning G (2008) Differences between measurements of bone mineral densities by quantitative ultrasound and dual-energy X-ray absorptiometry in type 2 diabetic postmenopausal women. J Clin Endocrinol Metab 93:1670–1675PubMedCrossRef Tao B, Liu JM, Zhao HY, Sun LH, Wang WQ, Li XY, Ning G (2008) Differences between measurements of bone mineral densities by quantitative ultrasound and dual-energy X-ray absorptiometry in type 2 diabetic postmenopausal women. J Clin Endocrinol Metab 93:1670–1675PubMedCrossRef
2.
Zurück zum Zitat Schwartz AV, Sellmeyer DE (2007) Diabetes, fracture, and bone fragility. Curr Osteoporos Rep 5:105–111PubMedCrossRef Schwartz AV, Sellmeyer DE (2007) Diabetes, fracture, and bone fragility. Curr Osteoporos Rep 5:105–111PubMedCrossRef
3.
Zurück zum Zitat Räkel A, Sheehy O, Rahme E, LeLorier J (2008) Osteoporosis among patients with type 1 and type 2 diabetes. Diab Metab 34:193–205CrossRef Räkel A, Sheehy O, Rahme E, LeLorier J (2008) Osteoporosis among patients with type 1 and type 2 diabetes. Diab Metab 34:193–205CrossRef
4.
Zurück zum Zitat McCabe LR (2007) Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102:1343–1357PubMedCrossRef McCabe LR (2007) Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102:1343–1357PubMedCrossRef
5.
Zurück zum Zitat Martin LM, McCabe LR (2007) Type I diabetic bone phenotype is location but not gender dependent. Histochem Cell Biol 128:125–133PubMedCrossRef Martin LM, McCabe LR (2007) Type I diabetic bone phenotype is location but not gender dependent. Histochem Cell Biol 128:125–133PubMedCrossRef
6.
Zurück zum Zitat Hofbauer LC, Brueck CC, Singh SK, Dobnig H (2007) Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22:1317–1328PubMedCrossRef Hofbauer LC, Brueck CC, Singh SK, Dobnig H (2007) Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22:1317–1328PubMedCrossRef
7.
Zurück zum Zitat Saller A, Maggi S, Romanato G, Tonin P, Crepaldi G (2008) Diabetes and osteoporosis. Aging Clin Exp Res 20:280–289PubMed Saller A, Maggi S, Romanato G, Tonin P, Crepaldi G (2008) Diabetes and osteoporosis. Aging Clin Exp Res 20:280–289PubMed
8.
Zurück zum Zitat Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731PubMedCrossRef Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731PubMedCrossRef
9.
Zurück zum Zitat Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:536–546 Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:536–546
10.
Zurück zum Zitat Altan MF, Kanter M, Donmez S, Kartal ME, Buyukbas S (2007) Combination therapy of Nigella sativa and human parathyroid hormone on bone mass, biomechanical behavior and structure in streptozotocin-induced diabetic rats. Acta Histochem 109:304–314PubMedCrossRef Altan MF, Kanter M, Donmez S, Kartal ME, Buyukbas S (2007) Combination therapy of Nigella sativa and human parathyroid hormone on bone mass, biomechanical behavior and structure in streptozotocin-induced diabetic rats. Acta Histochem 109:304–314PubMedCrossRef
11.
Zurück zum Zitat Ogasawara A, Nakajima A, Nakajima F, Goto K, Yamazaki M (2008) Molecular basis for affected cartilage formation and bone union in fracture healing of the streptozotocin-induced diabetic rat. Bone 43:832–839PubMedCrossRef Ogasawara A, Nakajima A, Nakajima F, Goto K, Yamazaki M (2008) Molecular basis for affected cartilage formation and bone union in fracture healing of the streptozotocin-induced diabetic rat. Bone 43:832–839PubMedCrossRef
12.
Zurück zum Zitat Yamaguchi M, Uchiyama S, Lai YL (2007) Oral administration of phytocomponent p-hydroxycinnamic acid has a preventive effect on bone loss in streptozotocin-induced diabetic rats. Int J Mol Med 19:803–807PubMed Yamaguchi M, Uchiyama S, Lai YL (2007) Oral administration of phytocomponent p-hydroxycinnamic acid has a preventive effect on bone loss in streptozotocin-induced diabetic rats. Int J Mol Med 19:803–807PubMed
13.
Zurück zum Zitat Kanter M, Altan MF, Donmez S, Ocakci A, Kartal ME (2007) The effects of quercetin on bone minerals, biomechanical behavior, and structure in streptozotocin-induced diabetic rats. Cell Biochem Funct 25:747–752PubMedCrossRef Kanter M, Altan MF, Donmez S, Ocakci A, Kartal ME (2007) The effects of quercetin on bone minerals, biomechanical behavior, and structure in streptozotocin-induced diabetic rats. Cell Biochem Funct 25:747–752PubMedCrossRef
14.
Zurück zum Zitat Uchiyama S, Yamaguchi M (2005) Oral administration of beta-cryptoxanthin prevents bone loss in streptozotocin-diabetic rats in vivo. Biol Pharm Bull 28:1766–1769PubMedCrossRef Uchiyama S, Yamaguchi M (2005) Oral administration of beta-cryptoxanthin prevents bone loss in streptozotocin-diabetic rats in vivo. Biol Pharm Bull 28:1766–1769PubMedCrossRef
15.
Zurück zum Zitat Suzuki K, Miyakoshi N, Tsuchida T, Kasukawa Y, Sato K, Itoi E (2003) Effects of combined treatment of insulin and human parathyroid hormone(1–34) on cancellous bone mass and structure in streptozotocin-induced diabetic rats. Bone 33:108–114PubMedCrossRef Suzuki K, Miyakoshi N, Tsuchida T, Kasukawa Y, Sato K, Itoi E (2003) Effects of combined treatment of insulin and human parathyroid hormone(1–34) on cancellous bone mass and structure in streptozotocin-induced diabetic rats. Bone 33:108–114PubMedCrossRef
16.
Zurück zum Zitat Yamaguchi M, Uchiyama S (2003) Preventive effect of zinc acexamate administration in streptozotocin-diabetic rats: restoration of bone loss. Int J Mol Med 12:755–761PubMed Yamaguchi M, Uchiyama S (2003) Preventive effect of zinc acexamate administration in streptozotocin-diabetic rats: restoration of bone loss. Int J Mol Med 12:755–761PubMed
17.
Zurück zum Zitat Motyl KJ, McCabe LR (2009) Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice. J Cell Physiol 218:376–384PubMedCrossRef Motyl KJ, McCabe LR (2009) Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice. J Cell Physiol 218:376–384PubMedCrossRef
18.
Zurück zum Zitat Hie M, Shimono M, Fujii K, Tsukamoto I (2007) Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. Bone 41:1045–1050PubMedCrossRef Hie M, Shimono M, Fujii K, Tsukamoto I (2007) Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. Bone 41:1045–1050PubMedCrossRef
19.
Zurück zum Zitat Quarles LD (2008) Endocrine functions of bone in mineral metabolism regulation. J Clin Investig 118:3820–3828PubMedCrossRef Quarles LD (2008) Endocrine functions of bone in mineral metabolism regulation. J Clin Investig 118:3820–3828PubMedCrossRef
20.
Zurück zum Zitat Zhang Y, Leung PC, Che CT, Chow HK, Wu CF, Wong MS (2008) Improvement of bone properties and enhancement of mineralization by ethanol extract of Fructus Ligustri Lucidi. Br J Nutr 99:494–502PubMed Zhang Y, Leung PC, Che CT, Chow HK, Wu CF, Wong MS (2008) Improvement of bone properties and enhancement of mineralization by ethanol extract of Fructus Ligustri Lucidi. Br J Nutr 99:494–502PubMed
21.
Zurück zum Zitat Zhang Y, Dong XL, Leung PC, Che CT, Wong MS (2008) Fructus ligustri lucidi extract improves calcium balance and modulates the calciotropic hormone level and vitamin D-dependent gene expression in aged ovariectomized rats. Menopause 15:558–565PubMedCrossRef Zhang Y, Dong XL, Leung PC, Che CT, Wong MS (2008) Fructus ligustri lucidi extract improves calcium balance and modulates the calciotropic hormone level and vitamin D-dependent gene expression in aged ovariectomized rats. Menopause 15:558–565PubMedCrossRef
22.
Zurück zum Zitat Zhang Y, Lai WP, Leung PC, Che CT, Wong MS (2008) Improvement of Ca balance by Fructus Ligustri Lucidi extract in aged female rats. Osteoporos Int 19:235–242PubMedCrossRef Zhang Y, Lai WP, Leung PC, Che CT, Wong MS (2008) Improvement of Ca balance by Fructus Ligustri Lucidi extract in aged female rats. Osteoporos Int 19:235–242PubMedCrossRef
23.
Zurück zum Zitat Strehler EE, Caride AJ, Filoteo AG, Xiong Y, Penniston JT, Enyedi A (2007) Plasma membrane Ca2+ ATPases as dynamic regulators of cellular calcium handling. Ann NY Acad Sci 1099:226–236PubMedCrossRef Strehler EE, Caride AJ, Filoteo AG, Xiong Y, Penniston JT, Enyedi A (2007) Plasma membrane Ca2+ ATPases as dynamic regulators of cellular calcium handling. Ann NY Acad Sci 1099:226–236PubMedCrossRef
24.
Zurück zum Zitat Zhang Y, Lai WP, Wu CF, Favus MJ, Leung PC, Wong MS (2007) Ovariectomy worsens secondary hyperparathyroidism in mature rats during low Ca diet. Am J Physiol Endocrinol Metab 292:E723–E731PubMedCrossRef Zhang Y, Lai WP, Wu CF, Favus MJ, Leung PC, Wong MS (2007) Ovariectomy worsens secondary hyperparathyroidism in mature rats during low Ca diet. Am J Physiol Endocrinol Metab 292:E723–E731PubMedCrossRef
25.
Zurück zum Zitat Hendrix I, Anderson P, May B, Morris H (2004) Regulation of gene expression by the CYP27B1 promoter-study of a transgenic mouse model. J Steroid Biochem Mol Biol 89–90:139–142PubMedCrossRef Hendrix I, Anderson P, May B, Morris H (2004) Regulation of gene expression by the CYP27B1 promoter-study of a transgenic mouse model. J Steroid Biochem Mol Biol 89–90:139–142PubMedCrossRef
26.
Zurück zum Zitat Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD (2005) Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628–2637PubMedCrossRef Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD (2005) Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628–2637PubMedCrossRef
27.
Zurück zum Zitat Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, Nyman JS, Wang X (2009) Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 24:1618–1627PubMedCrossRef Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, Nyman JS, Wang X (2009) Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 24:1618–1627PubMedCrossRef
28.
Zurück zum Zitat Yamaguchi T, Sugimoto T (2008) Calcium homeostasis and osteoporosis in diabetes mellitus and the metabolic syndrome. Clin Calcium 18:904–911PubMed Yamaguchi T, Sugimoto T (2008) Calcium homeostasis and osteoporosis in diabetes mellitus and the metabolic syndrome. Clin Calcium 18:904–911PubMed
29.
Zurück zum Zitat Lee CT, Lien YH, Lai LW, Chen JB, Lin CR, Chen HC (2006) Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. Kidney Int 69:1786–1791PubMedCrossRef Lee CT, Lien YH, Lai LW, Chen JB, Lin CR, Chen HC (2006) Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. Kidney Int 69:1786–1791PubMedCrossRef
30.
Zurück zum Zitat de Luis Román DA, Aller R, Perez Castrillon JL, De Luis J, Gonzalez Sagrado M, Izaola O, Romero E, Martín Escudero JC, Herreros V (2004) Effects of dietary intake and life style on bone density in patients with diabetes mellitus type 2. Ann Nutr Metab 48:141–145PubMedCrossRef de Luis Román DA, Aller R, Perez Castrillon JL, De Luis J, Gonzalez Sagrado M, Izaola O, Romero E, Martín Escudero JC, Herreros V (2004) Effects of dietary intake and life style on bone density in patients with diabetes mellitus type 2. Ann Nutr Metab 48:141–145PubMedCrossRef
31.
Zurück zum Zitat Diaz VA, Mainous AG 3rd, Carek PJ, Wessell AM, Everett CJ (2009) The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 22:521–527PubMedCrossRef Diaz VA, Mainous AG 3rd, Carek PJ, Wessell AM, Everett CJ (2009) The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 22:521–527PubMedCrossRef
32.
33.
Zurück zum Zitat Danescu LG, Levy S, Levy J (2009) Vitamin D and diabetes mellitus. Endocr 35:11–17CrossRef Danescu LG, Levy S, Levy J (2009) Vitamin D and diabetes mellitus. Endocr 35:11–17CrossRef
34.
Zurück zum Zitat Mathieu C, Gysemans C, Giulietti A, Bouillon R (2005) Vitamin D and diabetes. Diabetologia 48:1247–1257PubMedCrossRef Mathieu C, Gysemans C, Giulietti A, Bouillon R (2005) Vitamin D and diabetes. Diabetologia 48:1247–1257PubMedCrossRef
35.
Zurück zum Zitat Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, Chen Y, Zhang Z, Strugnell S, Sabbagh Y, Arbeeny CM, Li YC (2009) Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Ren Physiol 297:F791–F801CrossRef Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, Chen Y, Zhang Z, Strugnell S, Sabbagh Y, Arbeeny CM, Li YC (2009) Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Ren Physiol 297:F791–F801CrossRef
36.
Zurück zum Zitat Zhang Z, Zhang Y, Ning G, Kong J, Deb DK, Li YC (2008) Combination therapy with AT1 receptor blocker and vitamin D analog markedly ameliorates diabetic nephropathy. Proc Natl Acad Sci USA 105:15896–15901PubMedCrossRef Zhang Z, Zhang Y, Ning G, Kong J, Deb DK, Li YC (2008) Combination therapy with AT1 receptor blocker and vitamin D analog markedly ameliorates diabetic nephropathy. Proc Natl Acad Sci USA 105:15896–15901PubMedCrossRef
37.
38.
Zurück zum Zitat Baeke F, van Etten E, Gysemans C, Overbergh L, Mathieu C (2008) Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Aspects Med 29:376–387PubMedCrossRef Baeke F, van Etten E, Gysemans C, Overbergh L, Mathieu C (2008) Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Aspects Med 29:376–387PubMedCrossRef
39.
Zurück zum Zitat Panierakis C, Goulielmos G, Mamoulakis D, Petraki E, Papavasiliou E, Galanakis E (2009) Vitamin D receptor gene polymorphisms and susceptibility to type 1 diabetes in Crete, Greece. Clin Immunol 133:276–281PubMedCrossRef Panierakis C, Goulielmos G, Mamoulakis D, Petraki E, Papavasiliou E, Galanakis E (2009) Vitamin D receptor gene polymorphisms and susceptibility to type 1 diabetes in Crete, Greece. Clin Immunol 133:276–281PubMedCrossRef
40.
Zurück zum Zitat den Dekker E, Hoenderop JG, Nilius B, Bindels RJ (2003) The epithelial calcium channels, TRPV5 & TRPV6: from identification towards regulation. Cell Calcium 33:497–507CrossRef den Dekker E, Hoenderop JG, Nilius B, Bindels RJ (2003) The epithelial calcium channels, TRPV5 & TRPV6: from identification towards regulation. Cell Calcium 33:497–507CrossRef
41.
Zurück zum Zitat Boros S, Bindels RJ, Hoenderop JG (2009) Active Ca(2+) reabsorption in the connecting tubule. Pflugers Arch 458:99–109PubMedCrossRef Boros S, Bindels RJ, Hoenderop JG (2009) Active Ca(2+) reabsorption in the connecting tubule. Pflugers Arch 458:99–109PubMedCrossRef
42.
Zurück zum Zitat Ward DT, Yau SK, Mee AP, Mawer EB, Miller CA, Garland HO, Riccardi D (2001) Functional, molecular, and biochemical characterization of streptozotocin-induced diabetes. J Am Soc Nephrol 12:779–790PubMed Ward DT, Yau SK, Mee AP, Mawer EB, Miller CA, Garland HO, Riccardi D (2001) Functional, molecular, and biochemical characterization of streptozotocin-induced diabetes. J Am Soc Nephrol 12:779–790PubMed
43.
Zurück zum Zitat Kip SN, Strehler EE (2004) Vitamin D3 upregulates plasma membrane Ca2+-ATPase expression and potentiates apico-basal Ca2+ flux in MDCK cells. Am J Physiol Ren Physiol 286:F363–F369CrossRef Kip SN, Strehler EE (2004) Vitamin D3 upregulates plasma membrane Ca2+-ATPase expression and potentiates apico-basal Ca2+ flux in MDCK cells. Am J Physiol Ren Physiol 286:F363–F369CrossRef
44.
Zurück zum Zitat Reidy K, Susztak K (2009) Epithelial–mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis 54:590–593PubMedCrossRef Reidy K, Susztak K (2009) Epithelial–mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis 54:590–593PubMedCrossRef
Metadaten
Titel
Alteration of vitamin D metabolic enzyme expression and calcium transporter abundance in kidney involved in type 1 diabetes-induced bone loss
verfasst von
Y. Zhang
C. J. Papasian
H.-W. Deng
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 6/2011
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1404-1

Weitere Artikel der Ausgabe 6/2011

Osteoporosis International 6/2011 Zur Ausgabe

Bone Quality Seminars: Bone Fracture Healing and Strengthening

Bone fracture and bone fracture repair

Bone Quality Seminars: Bone Fracture Healing and Strengthening

Evaluation of bone scaffolds by micro-CT

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.